Studies on the topical action of 10-undecen-1-il thiopseudourea iodide (AHR-1911) in acute and chronic dermatitis.
As a follow-up of a preliminary trial, the therapeutic results obtained in 40 cases of acute and chronic dermatitis by the topical application of 10-undecen-1-yl-pseudothiourea hydroiodide (AHR-1911) in an evanescent vehicle containing triethanolamine stearate are presented. The treatment led to complete remission in 14/40 and to favorable results in 18/40 cases. In 2 out of 3 cases of infantile atopic dermatitis improvement was followed by relapse. The responsiveness to AHR-1911 of patients with delayed hypersensitivity, which requires steroids for treatment, is considered of clinical importance. The prompt action of the drug in acute dermatitis, such as is produced by insect-bites, appeared to be impressive. None of the total of 50 cases treated by the author with this new preparation showed any manifestation of intolerance or reaction to the drug.
D000208:Acute Disease; D000287:Administration, Topical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002648:Child; D002908:Chronic Disease; D003872:Dermatitis / Q000188:drug therapy*; D003877:Dermatitis, Contact / Q000188:drug therapy; D004341:Drug Evaluation; D004983:Ethanolamines; D006801:Humans; D007223:Infant; D007299:Insect Bites and Stings / Q000188:drug therapy*; D007550:Isothiuronium / Q000008:administration & dosage* / Q000627:therapeutic use; D014677:Pharmaceutical Vehicles; D013228:Stearates; D013890:Thiourea / Q000031:analogs & derivatives*
D000893:Anti-Inflammatory Agents; D004983:Ethanolamines; D014677:Pharmaceutical Vehicles; D013228:Stearates; C015555:triethanolamine stearate; D007550:Isothiuronium; D013890:Thiourea